[go: up one dir, main page]

WO2015075842A1 - Transcriptase inverse variante - Google Patents

Transcriptase inverse variante Download PDF

Info

Publication number
WO2015075842A1
WO2015075842A1 PCT/JP2013/081677 JP2013081677W WO2015075842A1 WO 2015075842 A1 WO2015075842 A1 WO 2015075842A1 JP 2013081677 W JP2013081677 W JP 2013081677W WO 2015075842 A1 WO2015075842 A1 WO 2015075842A1
Authority
WO
WIPO (PCT)
Prior art keywords
residue
reverse transcriptase
seq
amino acid
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2013/081677
Other languages
English (en)
Japanese (ja)
Inventor
保川　清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Priority to PCT/JP2013/081677 priority Critical patent/WO2015075842A1/fr
Publication of WO2015075842A1 publication Critical patent/WO2015075842A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/107—RNA dependent DNA polymerase,(i.e. reverse transcriptase)

Definitions

  • the present invention relates to a mutant reverse transcriptase. More specifically, the present invention relates to a mutant reverse transcriptase, a nucleic acid encoding the same, a reverse transcription method using the mutant reverse transcriptase, a reversal useful for gene analysis, disease inspection, useful gene cloning, and the like.
  • the present invention relates to a copy reaction kit and a detection kit.
  • Reverse transcriptase has an activity of synthesizing cDNA using RNA as a template (hereinafter referred to as “RNA-dependent DNA polymerase activity”).
  • RNA-dependent DNA polymerase activity Among the reverse transcriptases, Moloney murine leukemia virus reverse transcriptase (hereinafter referred to as “MMLV reverse transcriptase”) and avian myeloblastosis virus reverse transcriptase (hereinafter referred to as “removal transcriptase”) have high catalytic activity and accuracy.
  • MMLV reverse transcriptase Moloney murine leukemia virus reverse transcriptase
  • removal transcriptase avian myeloblastosis virus reverse transcriptase
  • AMV reverse transcriptase is widely used, for example, for gene analysis, disease testing, gene cloning, and the like.
  • MMLV reverse transcriptase can be easily produced as a soluble protein in Escherichia coli by genetic engineering techniques.
  • MMLV reverse transcriptase has a drawback that the reaction rate during cDNA synthesis is lower than that of AMV reverse transcriptase.
  • RNA has a base sequence that can easily form a secondary structure
  • synthesis of cDNA by reverse transcriptase is hindered by the secondary structure, and thus the formation of RNA secondary structure is suppressed by increasing the reaction temperature. It is desirable to synthesize cDNA.
  • wild-type reverse transcriptase has low thermal stability and may be inactivated at a temperature at which formation of RNA secondary structure is suppressed.
  • a mutant reverse transcriptase with improved heat resistance has been proposed (see, for example, Patent Document 1).
  • the mutant reverse transcriptase has the disadvantage of low industrial productivity. Therefore, there is a demand for a highly versatile reverse transcriptase that is excellent in industrial productivity, can be used under temperature conditions where the formation of RNA secondary structure is suppressed, can perform reverse transcription efficiently, and It has been.
  • the present invention has been made in view of the above prior art, and has excellent industrial productivity, high thermal stability, and efficient reversal even under temperature conditions in which the formation of RNA secondary structure is suppressed.
  • An object of the present invention is to provide a versatile mutant reverse transcriptase capable of performing a copying reaction.
  • Another object of the present invention is to provide a nucleic acid and a method for producing the mutant reverse transcriptase from which the mutant reverse transcriptase can be easily obtained.
  • the present invention also provides a versatile reverse transcription reaction kit and detection kit that can efficiently perform a reverse transcription reaction even under temperature conditions in which the formation of RNA secondary structure is suppressed. Objective.
  • an object of the present invention is to provide a reverse transcription method capable of performing a reverse transcription reaction efficiently even under temperature conditions in which the formation of RNA secondary structure is suppressed.
  • the gist of the present invention is as follows.
  • [1] A mutant reverse transcriptase having reverse transcriptase activity, Having the amino acid sequence corresponding to SEQ ID NO: 2, A domain corresponding to the connection domain in the wild-type reverse transcriptase consisting of the amino acid sequence shown in SEQ ID NO: 2; In the hydrophobic surface including a hydrophobic amino acid residue which is continuous in three-dimensional structure in the domain, at least one of the hydrophobic amino acid residues is substituted with a positively charged amino acid residue, Mutant reverse transcriptase, [2] A mutant reverse transcriptase having reverse transcriptase activity, which has an amino acid sequence corresponding to SEQ ID NO: 2, and in the amino acid sequence, a phenylalanine residue at position 303 of SEQ ID NO: 2, and position 432 Wherein the amino acid residue corresponding to at least one residue selected from the group consisting of a leucine residue, a valine residue at position 433, and an isoleucine residue at position 434 is substitute
  • Aspartic acid residue at position 108 in SEQ ID NO: 2 glutamic acid residue at position 117 in SEQ ID NO: 2
  • aspartic acid residue at position 124 in SEQ ID NO: 2 An amino acid residue corresponding to at least one residue selected from the group consisting of a glutamic acid residue at position 286 of SEQ ID NO: 2 and an aspartic acid residue at position 524 of SEQ ID NO: 2 is a positively charged amino acid residue
  • the amino acid sequence corresponding to SEQ ID NO: 2 is the phenylalanine residue at position 303 in SEQ ID NO: 2, the leucine residue at position 432 in SEQ ID NO: 2, and the valine residue at position 433 in SEQ ID NO: 2.
  • mutant inversion according to any one of [1] to [6] above, wherein the amino acid sequence has a conservative substitution of an amino acid residue excluding a residue corresponding to each of the isoleucine residues at position 434 of SEQ ID NO: 2.
  • the amino acid sequence corresponding to SEQ ID NO: 2 is (1) In the sequence shown in SEQ ID NO: 2, further substitution, deletion, insertion or addition of one or several amino acid residues in the sequence excluding the threonine residue at position 24 to the proline residue at position 474 is further performed.
  • the mutant reverse transcriptase of the present invention is excellent in industrial productivity, has high thermal stability, and can efficiently perform reverse transcription reaction even under temperature conditions in which the formation of RNA secondary structure is suppressed. And has a feature of high versatility. Moreover, the method for producing the nucleic acid of the present invention and the mutant reverse transcriptase of the present invention has an excellent effect that the mutant reverse transcriptase can be easily obtained. Furthermore, the reverse transcription reaction kit and detection kit of the present invention are characterized in that the reverse transcription reaction can be performed efficiently even under temperature conditions in which the formation of RNA secondary structure is suppressed, and the versatility is high. In addition, the reverse transcription method of the present invention has an excellent effect that the reverse transcription reaction can be performed efficiently even under temperature conditions in which the formation of RNA secondary structure is suppressed.
  • FIG. 3 is a schematic explanatory diagram showing the structure of a WT expression plasmid pET-MRT obtained in Production Example 1.
  • Test Example 2 it is a graph which shows the result of having investigated the relationship between a test sample and specific activity.
  • Test Example 2 it is a graph which shows the result of having investigated the relationship between a test sample and the residual activity after heat processing at 50 degreeC.
  • Experiment 3 it is a graph which shows the result of having investigated the relationship between a test sample and the residual activity after heat processing.
  • (A) is a graph showing the results of SDS-PAGE equivalent to a soluble fraction equivalent to 2.7 ⁇ L in Test Example 4, and (B) is a SDS-PAGE equivalent to a soluble fraction equivalent to 0.9 ⁇ L in Test Example 4. It is a graph which shows the result of having performed. In Experiment 5, it is a graph which shows the result of having investigated the relationship between a test sample and the residual activity after heat processing. It is a figure which shows the molecular model of the three-dimensional structure of the mutant
  • mutant reverse transcriptase of the present invention is a mutant reverse transcriptase having reverse transcriptase activity, Having the amino acid sequence corresponding to SEQ ID NO: 2, A domain corresponding to the connection domain in the wild-type reverse transcriptase consisting of the amino acid sequence shown in SEQ ID NO: 2; In the hydrophobic surface including a hydrophobic amino acid residue which is continuous in three-dimensional structure in the domain, at least one of the hydrophobic amino acid residues is substituted with a positively charged amino acid residue, To do.
  • the wild type reverse transcriptase consisting of the amino acid sequence shown in SEQ ID NO: 2 contains a Palm domain, Fingers domain, RNase H domain, Connection domain, and Thumb domain. Yes.
  • the “hydrophobic surface” is a portion including L432, V433, I434 and K435 in FIG.
  • the mutant reverse transcriptase of the present invention is a residue corresponding to a hydrophobic amino acid residue present on a hydrophobic surface including a hydrophobic amino acid residue that is continuous in three-dimensional structure in the connection domain of the wild type reverse transcriptase. Since the mutant reverse transcriptase of the present invention has an amino acid sequence in which at least one of the amino acid residues is substituted with a positively charged amino acid residue, Has a high residual activity compared to wild-type MMLV reverse transcriptase, and is expressed in cells such as E. coli cells compared to wild-type MMLV reverse transcriptase or other mutant reverse transcriptases. The level has improved. Therefore, the mutant reverse transcriptase of the present invention has high thermostability, can perform reverse transcription reaction efficiently even under temperature conditions where the formation of RNA secondary structure is suppressed, and is versatile. High and excellent in industrial productivity.
  • wild type means a naturally occurring one in which no mutation has been artificially introduced
  • mutant type means one in which a mutation has been artificially introduced.
  • sequence identity refers to a value calculated by alignment under the conditions of Gap Costs (Extension 11, Extension 1), Expect 10, and Word Size 3 by the BLAST algorithm.
  • hydrophobic amino acid residue examples include an amino acid residue corresponding to the phenylalanine residue at position 303 of SEQ ID NO: 2, an amino acid residue corresponding to the leucine residue at position 432 of SEQ ID NO: 2, and SEQ ID NO: 2 amino acid residues corresponding to the valine residue at position 433, amino acid residues corresponding to the isoleucine residue at position 434 in SEQ ID NO: 2, and the like, but the present invention is limited only to such examples is not.
  • the mutant reverse transcriptase of the present invention is, for example, a mutant reverse transcriptase having reverse transcriptase activity, having an amino acid sequence corresponding to SEQ ID NO: 2, and the amino acid sequence Amino acid corresponding to at least one residue selected from the group consisting of phenylalanine residue at position 303, leucine residue at position 432, valine residue at position 433, and isoleucine residue at position 434 in SEQ ID NO: 2
  • mutant reverse transcriptase characterized in that the residue is substituted with a positively charged amino acid residue but the present invention is not limited to such examples.
  • Such a mutant reverse transcriptase has a phenylalanine residue at position 303, a leucine residue at position 432, a valine residue at position 433, and an isoleucine residue at position 434 in the amino acid sequence corresponding to SEQ ID NO: 2. Since the amino acid residue corresponding to at least one residue selected from the group consisting of groups has an amino acid sequence substituted with a positively charged amino acid residue, formation of RNA secondary structure is suppressed. Even under temperature conditions, it has a high residual activity compared to wild-type MMLV reverse transcriptase. Therefore, the mutant reverse transcriptase of the present invention has high thermostability, can perform reverse transcription reaction efficiently even under temperature conditions where the formation of RNA secondary structure is suppressed, and is versatile.
  • the mutant reverse transcriptase of the present invention even when the template RNA has a base sequence that easily forms a secondary structure, the reaction temperature can be increased, and the RNA secondary structure can be increased. CDNA can be synthesized while suppressing the formation of.
  • the mutant reverse transcriptase of the present invention has an improved expression level in cells such as E. coli cells, for example, compared to wild-type MMLV reverse transcriptase or other mutant reverse transcriptases. Therefore, the mutant reverse transcriptase of the present invention is excellent in industrial productivity.
  • the reverse transcriptase activity is performed in the following steps 1) to 6): 1) Reaction solution [Composition: 25 mM Tris-HCl buffer (pH 8.3), 50 mM potassium chloride, 2 mM dithiothreitol, 5 mM magnesium chloride, 12.5 ⁇ M poly (rA) ⁇ p (dT) 15 (p (dT) 15 The equivalent concentration), and incubating the reverse transcriptase at 37 ° C.
  • dTTP uptake amount A step of calculating the amount of [ 3 H] dTTP taken into poly (rA) ⁇ p (dT) 15 (hereinafter referred to as “dTTP uptake amount”) based on the radioactivity obtained in step 4).
  • step 6 Based on the dTTP uptake calculated in step 5), the step of determining the amount of reverse transcriptase that incorporates 1 nmol of dTTP into poly (rA) ⁇ p (dT) 15 in 10 minutes is performed. Can be measured.
  • 1st position to 671th position of SEQ ID NO: 2 is the amino acid sequence of wild type MMLV reverse transcriptase. Note that positions 672 to 677 in SEQ ID NO: 2 are His tags composed of six histidine residues.
  • the “amino acid sequence corresponding to SEQ ID NO: 2” is 50% or more of the sequence identity with the amino acid sequence of wild-type MMLV reverse transcriptase or the sequence shown in SEQ ID NO: 2.
  • the sequence identity is preferably 70% or more, more preferably 80%, particularly preferably 100%, from the viewpoint of ensuring high thermal stability and ensuring sufficient specific activity.
  • the amino acid residue corresponding to the phenylalanine residue at position 303 of SEQ ID NO: 2 and the leucine residue at position 432 of SEQ ID NO: 2 Amino acid residues corresponding to the group, amino acid residues corresponding to the valine residue at position 433 of SEQ ID NO: 2 and amino acid residues corresponding to the isoleucine residue at position 434 of SEQ ID NO: 2, of these Three amino acid residues, two of these amino acid residues, or any one amino acid residue are replaced with positively charged amino acid residues.
  • the amino acid residue corresponding to the residue is preferably substituted with a positively charged amino acid residue.
  • the amino acid residue corresponding to the phenylalanine residue at position 303 of SEQ ID NO: 2 is the same as the amino acid sequence corresponding to SEQ ID NO: 2, but the GAP Costs (Existence 11) is compared with the sequence of SEQ ID NO: 2 by the BLAST algorithm.
  • Extension 1), Extract 10, and Word Size 3 are amino acid residues present at positions corresponding to the phenylalanine residue at position 303 in SEQ ID NO: 2.
  • the “amino acid residue corresponding to the leucine residue at position 432 of SEQ ID NO: 2” means that the amino acid sequence corresponding to SEQ ID NO: 2 is compared with the sequence of SEQ ID NO: 2 by the BLAST algorithm.
  • amino acid residue corresponding to the valine residue at position 433 of SEQ ID NO: 2 is the same as described above by using the BLAST algorithm for the amino acid sequence corresponding to SEQ ID NO: 2 with respect to the sequence of SEQ ID NO: 2.
  • amino acid residue corresponding to the isoleucine residue at position 434 of SEQ ID NO: 2 refers to the amino acid sequence corresponding to SEQ ID NO: 2 by the BLAST algorithm with respect to the sequence of SEQ ID NO: 2.
  • the amino acid residue which exists in the position corresponded to the isoleucine residue of the 434th position of sequence number: 2 when alignment is carried out on the same conditions as.
  • a positively charged amino acid residue refers to an amino acid residue that is positively charged at a pH suitable for carrying out a reverse transcription reaction (eg, pH 6.0 to 9.5).
  • the positively charged amino acid residue include an arginine residue and a lysine residue.
  • these positively charged amino acid residues they are positively charged at a pH suitable for conducting a reverse transcription reaction (for example, pH of 6.0 to 9.5), and have high thermal stability under such pH conditions.
  • Arginine residues and lysine residues are preferable because the property can be secured.
  • the mutant reverse transcriptase of the present invention ensures high thermostability and ensures sufficient specific activity, (A) substitution of a residue corresponding to the phenylalanine residue at position 303 of SEQ ID NO: 2 with a lysine residue or arginine residue; (B) substitution of a residue corresponding to the leucine residue at position 432 of SEQ ID NO: 2 with a lysine residue or an arginine residue; (C) substitution of a residue corresponding to a valine residue at position 433 in SEQ ID NO: 2 with a lysine residue or arginine residue; and (d) a residue corresponding to an isoleucine residue at position 434 in SEQ ID NO: 2. It preferably has at least one selected from the group consisting of substitution of a group with a lysine residue or arginine residue.
  • the mutant reverse transcriptase of the present invention has a threonine residue at position 24 to a proline residue at position 474 in SEQ ID NO: 2 in the amino acid sequence corresponding to SEQ ID NO: 2. It is preferable that at least one of the negatively charged amino acid residues among the amino acid residues localized in the corresponding region is substituted with the positively charged amino acid residue or the nonpolar amino acid residue.
  • region T24-P474 is the amino acid sequence corresponding to SEQ ID NO: 2.
  • region T24-P474 is the amino acid sequence corresponding to SEQ ID NO: 2.
  • Examples of the negatively charged amino acid residue include an aspartic acid residue and a glutamic acid residue.
  • the negatively charged amino acid residue has a shape as long as the polypeptide in which the negatively charged amino acid residue is substituted with the positively charged amino acid residue or the nonpolar amino acid residue can express reverse transcriptase activity. It may be a residue present at a position that causes a change in Specific examples of the negatively charged amino acid residue include an amino acid residue corresponding to the aspartic acid residue at position 108 of SEQ ID NO: 2, an amino acid residue corresponding to the glutamic acid residue at position 117 of SEQ ID NO: 2, and a sequence No.
  • aspartic acid residue at position 124 amino acid residue corresponding to glutamic acid residue at position 286 in SEQ ID NO: 2, amino acid residue corresponding to aspartic acid residue at position 524 in SEQ ID NO: 2, and the like
  • this invention is not limited only to this illustration.
  • aspartic acid at position 108 of SEQ ID NO: 2 in the sequence shown in SEQ ID NO: 2 from the viewpoint of ensuring high thermal stability and ensuring sufficient specific activity.
  • amino acid residue corresponding to at least one residue selected from the group consisting of residues is preferred.
  • nonpolar amino acid residues examples include alanine residues, glycine residues, valine residues, leucine residues, isoleucine residues, methionine residues, cysteine residues, tryptophan residues, phenylalanine residues, and proline residues. Etc.
  • an alanine residue is preferred because the size of the side chain is small and the shape change caused by substitution is considered to be small.
  • the mutant reverse transcriptase of the present invention ensures high thermostability and ensures sufficient specific activity, (I) an alanine residue, arginine residue, lysine residue, serine residue or threonine residue, preferably an alanine residue or arginine residue corresponding to the aspartic acid residue at position 108 of SEQ ID NO: 2 Replacement with, (II) To the alanine residue, arginine residue, lysine residue, serine residue or threonine residue of the residue corresponding to the glutamic acid residue at position 117 of SEQ ID NO: 2, preferably an alanine residue or arginine residue Replacement, (III) Alanine residue, arginine residue, lysine residue, serine residue or threonine residue, preferably alanine residue or arginine residue corresponding to the aspartic acid residue at position 124 of SEQ ID NO: 2 Replacement with, (IV) Substitution of a residue corresponding to the glutamic acid residue at position
  • substitution of an acid residue corresponding to an alanine or asparagine residue, preferably an alanine residue It is preferable to have at least one selected from the group consisting of:
  • the mutant reverse transcriptase of the present invention preferably has the substitution (V).
  • the amino acid sequence corresponding to SEQ ID NO: 2 is a phenylalanine residue at position 303 in SEQ ID NO: 2, a leucine residue at position 432 in SEQ ID NO: 2, It may be an amino acid sequence having a conservative substitution of amino acid residues except for a residue corresponding to a valine residue at position 433 and an isoleucine residue at position 434 of SEQ ID NO: 2.
  • conservative substitutions for example, a particular amino acid residue, hydrophobicity, charge, pK a, the amino acid residues that exhibits a function similar to the specific amino acid residues in terms of features on three-dimensional structure And the like.
  • conservative substitution include substitution of one amino acid residue belonging to any of the following groups I to VI with another amino acid residue belonging to the same group.
  • Group I Glycine and alanine residues
  • Group II Valine, isoleucine and leucine residues
  • Group III Aspartate, glutamate, asparagine and glutamine residues
  • Group IV Serine and Threonine residue
  • Group V Arginine residue and lysine residue
  • Group VI Phenylalanine residue and tyrosine residue
  • the amino acid sequence corresponding to SEQ ID NO: 2 is within the range that does not interfere with the object of the present invention.
  • substitution, deletion, insertion or addition of one or several amino acid residues means substitution, deletion, insertion or addition of a number of amino acid residues within a range showing reverse transcriptase activity.
  • the “one or several” means 1 to 30.
  • the “one or several” is preferably 1 to 20, more preferably 1 to 10, still more preferably 1 to 3, particularly preferably 1 or 2.
  • sequence identity is at least 80%, preferably 90% or more, more preferably 95% or more, particularly preferably 100% from the viewpoint of ensuring high thermal stability and ensuring sufficient specific activity. is there.
  • the mutant reverse transcriptase of the present invention ensures higher thermal stability and from the viewpoint of ensuring high industrial productivity, i) substitution of a residue corresponding to a valine residue at position 433 of SEQ ID NO: 2 with a lysine residue or an arginine residue; ii) substitution of the residue corresponding to the aspartic acid residue at position 108 of SEQ ID NO: 2 with an alanine residue, lysine residue or arginine residue; and iii) the glutamic acid residue at position 286 of SEQ ID NO: 2.
  • Mutant reverse transcriptase having a substitution of the corresponding residue to an alanine residue, lysine residue or arginine residue, and (iv) aspartic acid at position 524 of SEQ ID NO: 2 in addition to i) to iii) above
  • a mutant reverse transcriptase further having a substitution of a residue corresponding to the residue with an alanine residue, lysine residue or arginine residue is preferred.
  • the mutant reverse transcriptase of the present invention is excellent in industrial productivity, has high thermal stability, and efficiently reverses even under temperature conditions in which the formation of RNA secondary structure is suppressed. Since it can perform photoreaction and is highly versatile, it is useful for gene analysis, examination of diseases, and cloning of useful genes.
  • nucleic acid encoding mutant reverse transcriptase The nucleic acid of the present invention is a nucleic acid encoding the mutant reverse transcriptase of the present invention. Since the nucleic acid of the present invention encodes the mutant reverse transcriptase, the mutant reverse transcriptase can be easily obtained by expressing the mutant reverse transcriptase encoded by the nucleic acid.
  • nucleic acid examples include DNA and mRNA, but the present invention is not limited to such examples.
  • the nucleic acid of the present invention is, for example, a nucleic acid consisting of a base sequence corresponding to SEQ ID NO: 1, A positive amino acid residue corresponding to at least one residue selected from the group consisting of a valine residue at position 433 and an isoleucine residue at position 434 in the amino acid sequence corresponding to SEQ ID NO: 2; Substitution to a charged amino acid residue, -Substitution of at least any positively charged amino acid residue or nonpolar amino acid residue of a negatively charged amino acid residue among amino acid residues localized in region T24-P474 in the amino acid sequence corresponding to SEQ ID NO: 2 Can be obtained by introducing site-specific mutations so as to cause such mutations.
  • positions 2014 to 2034 in SEQ ID NO: 1 are the nucleotide sequence of a nucleic acid encoding a His tag consisting of six histidine residues.
  • the “base sequence corresponding to SEQ ID NO: 1” has a nucleotide sequence of 50% or more of the nucleotide sequence of a nucleic acid encoding wild-type MMLV reverse transcriptase or the sequence shown in SEQ ID NO: 2, and is wild A nucleotide sequence of a nucleic acid encoding a reverse transcriptase exhibiting reverse transcriptase activity under the same conditions as type MMLV reverse transcriptase.
  • the introduction of site-specific mutation into the nucleic acid is, for example, a non-PCR method using a non-PCR primer designed to cause the mutation, a PCR method using a PCR primer designed to cause the mutation Etc.
  • the mutant reverse transcriptase of the present invention since the nucleic acid of the present invention encodes the mutant reverse transcriptase of the present invention, the mutant reverse transcriptase of the present invention can be easily obtained. It is useful for industrial production.
  • the mutant reverse transcriptase of the present invention can be obtained by expressing the mutant reverse transcriptase encoded by the nucleic acid using the nucleic acid of the present invention.
  • the present invention also includes a method for producing such a mutant reverse transcriptase.
  • the production method of the present invention is a method for producing the aforementioned mutant reverse transcriptase, (A) a step of culturing cells retaining the nucleic acid of the present invention to express a mutant reverse transcriptase encoded by the nucleic acid to obtain a culture, and (B) a mutation from the culture obtained in the step It is a method characterized by including the process of collect
  • cells retaining the nucleic acid of the present invention are cultured to express a mutant reverse transcriptase encoded by the nucleic acid to obtain a culture [“Step (A)”].
  • the cell retaining the nucleic acid can be obtained, for example, by transforming a host cell with a gene introduction carrier containing the nucleic acid.
  • Examples of the host cell include bacterial cells such as E. coli, insect cells, yeast cells, plant cells, and animal cells, but the present invention is not limited to such examples. Among these, bacterial cells are preferable, and Escherichia coli cells are more preferable because the mutant reverse transcriptase can be easily purified and the mutant reverse transcriptase can be produced in large quantities.
  • Examples of the E. coli cells include BL21 (DE3), but the present invention is not limited to such examples.
  • the gene introduction carrier may be a biological carrier or a non-biological carrier.
  • biological carriers include vectors such as plasmid vectors, phage vectors, and viral vectors, but the present invention is not limited to such examples.
  • non-biological carrier include gold particles, dextran, and liposomes, but the present invention is not limited to such examples.
  • Such a carrier for gene transfer can be appropriately selected depending on the host cell to be used. For example, when a cell of BL21 (DE3) which is Escherichia coli is used as a host cell, a pET plasmid vector can be used. In this case, the mutant reverse transcriptase can be expressed in a large amount, and the mutant reverse transcriptase can be easily purified.
  • the vector may be a secretory vector that secretes the protein outside the cell, or an intracellular expression vector that accumulates the protein inside the cell.
  • the vector may contain elements for facilitating purification of the mutant reverse transcriptase, such as a His tag and an extracellular secretion signal.
  • the gene introduction carrier is a vector that is the biological carrier
  • the gene introduction carrier is inserted into the vector cloning site by inserting the nucleic acid and operably linked under the control of a promoter.
  • operably linked means that the expression of a polypeptide encoded by a nucleic acid is linked so that it is expressed in a state exhibiting biological activity under the control of an element such as a promoter.
  • the carrier for gene introduction is the non-biological carrier
  • the carrier for gene introduction is a nucleic acid construct obtained by operably linking the nucleic acid under the control of a promoter, if necessary. , And can be prepared by supporting the non-biological carrier.
  • a nucleic acid construct may appropriately contain elements necessary for expression of a gene such as a replication origin and a terminator.
  • the introduction of the carrier for gene introduction into the host cell can be performed by a method according to the type of carrier used for gene introduction, the type of host cell, and the like.
  • a transformation method include a transfection method, an electroporation method, a calcium phosphate method, a DEAE-dextran method, and a particle gun method, but the present invention is not limited to such examples.
  • the culture condition of the cell holding the nucleic acid varies depending on the type of the host cell used, and therefore cannot be determined unconditionally. Accordingly, it is preferable to set appropriately.
  • the nucleic acid is operably linked under the control of an inducible promoter
  • cells that retain the nucleic acid may be cultured under expression-inducing conditions according to the type of the promoter.
  • the mutant reverse transcriptase is recovered from the culture obtained in the step (A) [“Step (B)”].
  • the culture is subjected to centrifugation, filtration, etc. to recover the culture supernatant, and the mutant reverse transcriptase in the culture supernatant is purified.
  • methods for performing such purification include centrifugation, ultracentrifugation, ultrafiltration, salting out, dialysis, ion exchange column chromatography, adsorption column chromatography, affinity chromatography, and gel filtration column chromatography. The present invention is not limited to such examples.
  • step (B) when the mutant reverse transcriptase is accumulated in the cells in the culture, in step (B), the culture is subjected to centrifugation or the like to recover the cells, and the mutant reversal is obtained from the cell disruption.
  • the transcriptase can be isolated.
  • the cells are disrupted by ultrasonic disruption, lysis, freeze disruption, etc., and then the mutant reverse transcriptase in the cell-free extract obtained from the obtained disrupted product is purified to obtain a single cell. Can be separated.
  • mutant reverse transcription is carried out in the cell.
  • the enzyme can be expressed in large quantities, and after the collected cells are crushed, the extract obtained from the crushed material is subjected to anion exchange column chromatography and nickel affinity chromatography. Can be easily purified.
  • the mutant reverse transcriptase can be easily obtained. Useful for industrial production of reverse transcriptase.
  • the reverse transcription method of the present invention is characterized by synthesizing cDNA from RNA using the mutant reverse transcriptase of the present invention.
  • the mutant reverse transcriptase of the present invention has a higher thermal stability than the wild type reverse transcriptase. Therefore, according to the reverse transcription method of the present invention, the reverse transcription reaction can be performed in a wide temperature range including the temperature at which the formation of RNA secondary structure is suppressed. Therefore, the reverse transcription method of the present invention can use various RNAs as templates, and can perform a reverse transcription reaction efficiently.
  • the mutant reverse transcriptase, RNA, an oligonucleotide primer complementary to the RNA, and four types of deoxyribonucleoside triphosphates are incubated in a reverse transcription reaction buffer.
  • a reverse transcription reaction can be performed.
  • the reaction temperature in the reverse transcription reaction varies depending on the type of RNA used, the type of mutant reverse transcriptase used, etc., it cannot be determined unconditionally, so the type of RNA used, the type of mutant reversal used It is preferable to set appropriately according to the type of the coenzyme.
  • the reaction temperature can be set to the optimum reaction temperature, for example, when the RNA used is an RNA that does not readily form a secondary structure at the optimum reaction temperature of wild-type reverse transcriptase.
  • the reaction temperature is higher than the optimum reaction temperature of the wild-type reverse transcriptase, for example, when the RNA used is an RNA that easily forms a secondary structure at the optimum reaction temperature of the wild-type reverse transcriptase.
  • the temperature can be set to 45 to 65 ° C.
  • the concentration of the reverse transcriptase in the reaction system during the reverse transcription reaction varies depending on the use of the reverse transcription method of the present invention and the like, it cannot be determined unconditionally, so it is appropriately set according to the use etc. It is preferable.
  • the concentration of the reverse transcriptase is usually 0.001 to 0.1 ⁇ M.
  • the concentration of the oligonucleotide primer in the reaction system during the reverse transcription reaction is usually 0.1 to 10 ⁇ M.
  • concentration of the four types of deoxyribonucleoside triphosphates in the reaction system during the reverse transcription reaction varies depending on the concentration and length of the target RNA, it cannot be determined in general. It is preferable to set appropriately depending on the concentration and length of RNA to be obtained.
  • concentration of the four deoxyribonucleoside triphosphates is usually 0.01 to 1 ⁇ M.
  • the reverse transcription reaction buffer can be appropriately selected according to the type of mutant reverse transcriptase used.
  • the reverse transcription reaction buffer may contain a divalent cation, such as magnesium ion or manganese ion.
  • the reverse transcription reaction buffer is not limited to the purpose of the present invention, and if necessary, a reducing agent (for example, dithiothreitol), a stabilizer (for example, glycerol, trehalose, etc.), organic Components such as a solvent (for example, dimethyl sulfoxide, formamide, etc.) may be contained.
  • the concentration of the divalent cation in the reverse transcription reaction buffer varies depending on the type of reverse transcriptase and other components contained in the reverse transcription reaction buffer. Therefore, it is preferable to set appropriately depending on the type of reverse transcriptase and other components contained in the buffer for reverse transcription reaction.
  • the concentration of the divalent cation is usually 1 to 30 mM.
  • the pH of the reverse transcription reaction buffer solution varies depending on the type of reverse transcriptase and other components contained in the reverse transcription reaction buffer solution, it cannot be generally determined. It is preferable to set appropriately depending on the type of the above and other components contained in the reverse transcription reaction buffer.
  • the pH of the reverse transcription reaction buffer is generally 6.0 to 9.5.
  • the reverse transcription method of the present invention is used in the reverse transcription method of the present invention, the reverse transcription reaction is efficiently performed even under temperature conditions in which the formation of RNA secondary structure is suppressed. Since it is highly versatile, it is useful for gene analysis, examination of diseases, cloning of useful genes, and the like.
  • the reverse transcription reaction kit of the present invention is a kit for carrying out a reverse transcription reaction, and is characterized by containing the mutant reverse transcriptase of the present invention. Since the reverse transcription reaction kit of the present invention contains the mutant reverse transcriptase of the present invention having high thermal stability, the reverse transcription in a wide temperature range including the temperature at which the formation of RNA secondary structure is suppressed. Suitable for photoreaction. Therefore, the reverse transcription reaction kit of the present invention is highly versatile because the reverse transcription reaction can be efficiently performed regardless of the type of RNA. Since the reverse transcription reaction kit of the present invention contains the mutant reverse transcriptase of the present invention, it is excellent in industrial productivity.
  • the reverse transcription reaction kit of the present invention may contain a reagent necessary for performing a reverse transcription reaction in addition to the mutant reverse transcriptase.
  • a reagent necessary for performing a reverse transcription reaction in addition to the mutant reverse transcriptase.
  • examples of such a reagent include RNA used as a template for a reverse transcription reaction, oligonucleotide primers complementary to the RNA, four types of deoxyribonucleoside triphosphates, a buffer for reverse transcription reaction, an organic solvent, and the like.
  • the reverse transcription reaction buffer is the same as the reverse transcription reaction buffer used in the reverse transcription method.
  • the mutant reverse transcriptase may be enclosed in a container containing a storage buffer containing a stabilizer such as glycerol or trehalose.
  • a storage buffer include a buffer having a pH corresponding to the pH stability of the mutant reverse transcriptase.
  • the reagent necessary for performing the reverse transcription reaction may be enclosed in a container different from the container containing the mutant reverse transcriptase, and the progress of the reverse transcription reaction during storage of the reagent. May be enclosed in the same container as the mutant reverse transcriptase.
  • the reagent may be enclosed in a container so as to have an amount suitable for performing a reverse transcription reaction. This eliminates the need for the user to mix each reagent in an amount suitable for the reverse transcription reaction, and is easy to handle.
  • the reverse transcription enzyme of the present invention is used in the reverse transcription reaction kit of the present invention, reverse transcription is efficiently performed even under temperature conditions in which the formation of RNA secondary structure is suppressed. Since the reaction can be performed and the versatility is high, it is suitable for performing a reverse transcription reaction in gene analysis, examination of diseases, cloning of useful genes, and the like.
  • the detection kit of the present invention is a kit for detecting a marker in a sample containing RNA obtained from a living body, and contains the mutant reverse transcriptase and the reagent for detecting the marker. It is a feature. Since the detection kit of the present invention contains the mutant reverse transcriptase having high thermostability, it is suitable for a reverse transcription reaction in a wide temperature range including a temperature at which formation of RNA secondary structure is suppressed. It is. Therefore, the detection kit of the present invention can be used for various samples and is highly versatile. Moreover, since the detection kit of the present invention contains the mutant reverse transcriptase of the present invention, it is excellent in industrial productivity.
  • the marker examples include RNA having a base sequence peculiar to viruses or bacteria contained in a living body, a base sequence peculiar to a disease, and the like.
  • the “base sequence peculiar to a virus or a bacterium” refers to a base sequence that exists in a virus or bacterium but does not exist in a living body.
  • the “base sequence peculiar to a disease” refers to a base sequence that exists in a living body affected with a disease but does not exist in a normal living body that does not suffer from the disease.
  • the virus is not particularly limited, and examples thereof include HPV, HIV, influenza virus, HCV, Norovirus, West Nile virus and the like.
  • examples of the bacterium include Bacillus cereus, Salmonella, enterohemorrhagic Escherichia coli, Vibrio, Campylobacter, and methicillin-resistant Staphylococcus aureus that cause food poisoning.
  • examples of the disease include cancer, diabetes, heart disease, high blood pressure, and infectious diseases.
  • the reagent for detecting the marker examples include a probe that is complementary to the RNA serving as the marker and bound with a fluorescent substance or a radioactive substance, or a fluorescent substance that specifically intercalates with a double-stranded nucleic acid (for example, Ethidium bromide).
  • the detection kit of the present invention includes, for example, four types of deoxyribonucleoside triphosphates, a reverse transcription reaction buffer, an organic solvent, RNA serving as a positive control, It may contain RNA that serves as a negative control.
  • the reverse transcription reaction buffer is the same as the reverse transcription reaction buffer used in the reverse transcription method.
  • the mutant reverse transcriptase may be enclosed in a container containing a storage buffer containing a stabilizer such as glycerol or trehalose.
  • a storage buffer solution is the same as the storage buffer solution in the reverse transcription reaction kit.
  • the four types of deoxyribonucleoside triphosphates, reverse transcription reaction buffer, and the like may be sealed in a container different from the container containing the mutant reverse transcriptase, and the reagent may be stored. As long as the progress of the reverse transcription reaction therein is stopped, it may be enclosed in the same container as the mutant reverse transcriptase. From the same viewpoint as in the case of the reverse transcription reaction kit, the reagent may be enclosed in a container so as to have an amount suitable for performing the reverse transcription reaction.
  • the detection kit of the present invention uses the mutant reverse transcriptase of the present invention, the detection kit can efficiently perform reverse transcription reaction even under temperature conditions in which the formation of RNA secondary structure is suppressed. Since it can be performed, the versatility is high, and a base sequence peculiar to a virus or bacteria or a base sequence peculiar to a disease can be detected with high accuracy regardless of the kind of RNA used as a test sample.
  • Production Example 1 A DNA (SEQ ID NO: 1) encoding wild type MMLV reverse transcriptase (hereinafter also simply referred to as “WT”) was inserted into the pET-22b (+) plasmid to obtain a WT expression plasmid pET-MRT.
  • the WT expression plasmid expresses WT as a His tag polypeptide with (His) 6 added to the C-terminus.
  • the structure of the WT expression plasmid pET-MRT obtained in Production Example 1 is shown in FIG.
  • Example 1 Using the pET-MRT obtained in Production Example 1, a primer pair for V433R, and a site-specific mutation kit (manufactured by Stratagene, trade name: Quikchange TM site-directed mutagenesis kit), pET- A point expression mutation causing substitution of a valine residue at position 433 of SEQ ID NO: 2 to an arginine residue was introduced into DNA encoding WT contained in MRT to obtain a mutant expression plasmid. Whether or not a predetermined point mutation was introduced into the DNA contained in the obtained mutant expression plasmid was confirmed by a DNA sequencer [manufactured by Shimadzu Corporation, trade name: DSQ-2000].
  • V433R indicates substitution of an amino acid residue corresponding to the valine residue at position 433 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • the primers constituting the V433R primer pair are as shown in Table 1.
  • Table 1 the underlined portion indicates a sequence mismatched with DNA encoding WT contained in pET-MRT.
  • the obtained mutant expression plasmid was used to transform E. coli BL21 (DE3), which is a host cell.
  • the obtained cells were cultured at 37 ° C. in L broth [composition: 1% by mass tryptone, 0.5% by mass yeast extract, 1% by mass sodium chloride and the remaining water] containing 50 ⁇ g / mL ampicillin for transformation. Cells were obtained.
  • the transformed cells were inoculated into 3 mL of L broth containing 50 ⁇ g / mL ampicillin and incubated at 37 ° C. for 16 hours with shaking to obtain a culture solution.
  • 2 mL of the culture solution was added to 3 mL of L broth containing 50 ⁇ g / mL ampicillin, and the transformed cells were incubated at 37 ° C. for 2 hours.
  • 200 ⁇ L of 0.5 M isopropyl- ⁇ -thiogalactopyranoside (IPTG) aqueous solution was added, and the transformed cells were incubated at 30 ° C. for 4 hours to express the protein.
  • IPTG isopropyl- ⁇ -thiogalactopyranoside
  • the obtained culture was subjected to centrifugation at 5840 ⁇ g for 10 minutes to collect cells.
  • the collected cells were suspended in 20 mL of buffer A [composition: 20 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 volume% glycerol, pH 7.2] and disrupted by sonication.
  • the obtained crushed material was subjected to centrifugation at 20000 ⁇ g for 20 minutes, and the supernatant was recovered.
  • the collected supernatant was subjected to anion using a column (2.5 ⁇ 12 cm) packed with anion exchange resin [trade name: Toyopearl DEAE-650M, manufactured by Tosoh Corp.] equilibrated with buffer A.
  • the sample was subjected to ion exchange column chromatography. After the column was washed with the buffer A to remove non-adsorbed protein from the column, the buffer B [composition: 300 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 vol% glycerol, pH 7. 2] was used to elute the protein adsorbed on the column to obtain a fraction showing reverse transcriptase activity.
  • the buffer B composition: 300 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 vol% glycerol, pH 7. 2
  • the obtained fraction was purified with a histidine tag binding protein parallelized with buffer C [composition: 20 mM imidazole, 20 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 vol% glycerol, pH 7.2].
  • buffer C Composition: 20 mM imidazole, 20 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 vol% glycerol, pH 7.2].
  • the sample was applied to a prepacked column (manufactured by GE Healthcare, trade name: HisTrap HP 1 mL). After removing the non-adsorbed protein from the column by washing the column with buffer D [composition: 80 mM imidazole, 20 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 vol% glycerol, pH 7.2].
  • the protein adsorbed on the column was eluted with buffer E [composition: 500 mM imidazole, 20 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 10 volume% glycerol, pH 7.2], and reverse transcriptase activity An affinity-purified fraction showing was obtained.
  • the obtained fraction was dialyzed against buffer F [composition: 20 mM potassium phosphate buffer, 2.0 mM dithiothreitol and 50 vol% glycerol, pH 7.2], and in the sequence shown in SEQ ID NO: 2.
  • a mutant reverse transcriptase (V433R) having an amino acid sequence in which the valine residue at position 433 was substituted with an arginine residue was obtained.
  • Example 1 instead of using the V433R primer pair as a primer pair, a V433K primer pair (Example 2), an I434R primer pair (Example 3) or an I434K primer pair (Example 4) was used.
  • mutant reverse transcriptase (V433K) having the amino acid sequence in which the valine residue at position 433 in the sequence shown in SEQ ID NO: 2 was replaced with a lysine residue was performed in the same manner as in Example 1 except for Example 2), mutant reverse transcriptase (I434R) having an amino acid sequence in which the isoleucine residue at position 434 in the sequence shown in SEQ ID NO: 2 is substituted with an arginine residue (Example 3) or SEQ ID NO: Mutant reverse transcriptase (I434K) having an amino acid sequence in which the isoleucine residue at position 434 in the sequence shown in FIG. ⁇ 4) was obtained.
  • V433K is a substitution of an amino acid residue corresponding to the valine residue at position 433 in the sequence shown in SEQ ID NO: 2 with a lysine residue
  • I434R is in the sequence shown in SEQ ID NO: 2.
  • Substitution of amino acid residue corresponding to isoleucine residue at position 434 to arginine residue and “I434K” is a lysine residue of amino acid residue corresponding to isoleucine residue at position 434 in the sequence shown in SEQ ID NO: 2 Indicates a replacement for.
  • the primers constituting each primer pair are as shown in Table 1.
  • Example 1 instead of using the V433R primer pair as the primer pair, the same operation as in Example 1 was used, except that the L304R primer pair (Comparative Example 1) or the L304K primer pair (Comparative Example 2) was used.
  • L304R mutant reverse transcriptase
  • SEQ ID NO: 2 mutant reverse transcriptase
  • SEQ ID NO: 2 mutant reverse transcriptase having an amino acid sequence in which the leucine residue at position 304 in the sequence shown in SEQ ID NO: 2 is substituted with an arginine residue.
  • L304R is a substitution of an amino acid residue corresponding to the leucine residue at position 304 in the sequence shown in SEQ ID NO: 2 with an arginine residue
  • L304K is in the sequence shown in SEQ ID NO: 2.
  • the substitution of an amino acid residue corresponding to the leucine residue at position 304 to a lysine residue is shown.
  • the primers constituting each primer pair are as shown in Table 1.
  • Example 3 instead of transforming E. coli BL21 (DE3) with the mutant expression plasmid, E. coli BL21 (DE3) was transformed with the WT expression plasmid obtained in Production Example 1, The same operation as in Example 1 was performed to obtain WT.
  • Test example 1 As a test sample, a dialysis fraction containing the mutant reverse transcriptase obtained in Example 1, 2, 3 or 4 or Comparative Example 1 or 2 was used as sodium dodecyl sulfate-denatured polyacrylamide gel electrophoresis (hereinafter referred to as “SDS”). -PAGE "). As a result, the dialysis fractions containing the mutant reverse transcriptase obtained in Examples 1 to 4 and Comparative Examples 1 and 2 all showed a single band of 75 kDa.
  • SDS sodium dodecyl sulfate-denatured polyacrylamide gel electrophoresis
  • Test example 2 (1) Measurement of reverse transcriptase activity and specific activity As a test sample, the mutant reverse transcriptase obtained in Example 1, 2, 3 or 4, Comparative Example 1 or 2 or WT obtained in Comparative Example 3 was used. Reverse transcription reaction was performed using the contained dialysis fraction.
  • the composition of the reaction solution used in the reverse transcription reaction was 30 nM mutant reverse transcriptase or WT, 25 mM Tris-HCl buffer (pH 8.3), 50 mM potassium chloride, 2 mM dithiothreitol, 5 mM magnesium chloride, 12.5 ⁇ M poly (RA) ⁇ p (dT) 15 [concentration p (dT) 15 ] and 0.2 mM [methyl- 3 H] dTTP (1.85 Bq / pmol) (manufactured by GE Healthcare).
  • the volume of the reaction solution used for the reverse transcription reaction is 72 ⁇ L.
  • the reverse transcription reaction was performed by incubating the reaction solution at 37 ° C.
  • the glass filter was dried.
  • the glass filter was placed in 2.5 mL of a liquid scintillation reagent (trade name: Ecoscint H, manufactured by National Diagnostics), and the radioactivity was counted. Based on the radioactivity, the amount of [ 3 H] dTTP incorporated into poly (rA) ⁇ p (dT) 15 (referred to as “dTTP incorporation”) was calculated.
  • the initial reaction rate was calculated based on the change over time in the amount of dTTP uptake, and the reverse transcriptase activity was calculated.
  • One unit in reverse transcriptase activity was defined as the amount of reverse transcriptase that incorporated 1 nmol of dTTP into poly (rA) ⁇ p (dT) 15 in 10 minutes.
  • lane 1 is the mutant reverse transcriptase (V433R) obtained in Example 1
  • lane 2 is the mutant reverse transcriptase (V433K) obtained in Example 2
  • lane 3 is obtained in Example 3.
  • Mutant reverse transcriptase (I434R) Lane 4 is the mutant reverse transcriptase (I434R) obtained in Example 4
  • Lane 5 is the mutant reverse transcriptase (L304R) obtained in Comparative Example 1
  • Lane 7 represents the WT obtained in Comparative Example 3.
  • each of the mutant reverse transcriptases obtained in Examples 1 to 4 has a specific activity (40000 units / mg) that is generally considered to be practically sufficient. I understand that. In contrast, the specific activities of the mutant reverse transcriptases obtained in Comparative Examples 1 and 2 are both extremely low, indicating that they are unsuitable for practical use.
  • the mutant reverse transcriptase obtained in Example 1, 2, 3 or 4 or the WT obtained in Comparative Example 3 has a concentration of the mutant reverse transcriptase or WT of 30 nM.
  • 200 ⁇ L of the incubation solution [composition: 10 mM potassium phosphate buffer (pH 7.6), 2 mM dithiothreitol, 0.2 vol% Triton TM X-100 and 10 vol% glycerol] was added.
  • the mutant reverse transcriptase obtained in Example 1, 2, 3 or 4 or the WT obtained in Comparative Example 3 was subjected to heat treatment. did.
  • a mixture containing mutant reverse transcriptase after heat treatment or WT after heat treatment was incubated on ice for 30 to 60 minutes.
  • the mutant reverse transcriptase after the heat treatment or the WT after the heat treatment is added to the reaction solution so that the concentration of the mutant reverse transcriptase after the heat treatment or the WT after the heat treatment is 30 nM.
  • the resulting mixture was incubated at 37 ° C. to perform a reverse transcriptase reaction.
  • the glass filter was dried.
  • the glass filter was placed in 2.5 mL of a liquid scintillation reagent (National Diagnostics, product name: Ecoscint H), and the radioactivity was counted with a liquid scintillation counter. The dTTP uptake amount was calculated based on the radioactivity.
  • the initial reaction rate was calculated based on the change in dTTP uptake over time.
  • the residual activity was calculated from the initial reaction rate when the heat treatment was not performed (referred to as “initial reaction rate A”) and the initial reaction rate when the heat treatment was performed (referred to as “initial reaction rate B”).
  • Example 2 the results of examining the relationship between the test sample and the residual activity after heat treatment at 50 ° C. are shown in FIG.
  • lane 1 is the mutant reverse transcriptase (V433R) obtained in Example 1
  • lane 2 is the mutant reverse transcriptase (V433K) obtained in Example 2
  • lane 3 is obtained in Example 3.
  • lane 4 shows the mutant reverse transcriptase (I434R) obtained in Example 4
  • lane 5 shows the WT obtained in Comparative Example 3.
  • the mutant reverse transcriptase (V433R) obtained in Example 1, the mutant reverse transcriptase (V433K) obtained in Example 2, and the mutant type obtained in Example 3 were used.
  • the residual activity of the reverse transcriptase (I434R) and the mutant reverse transcriptase (I434R) obtained in Example 4 after heat treatment at 50 ° C. (lanes 1 to 4) is the residual activity of WT after heat treatment at 50 ° C. It can be seen that it is higher than the activity (lane 5).
  • the initial reaction rate after heat treatment at 50 ° C. of each of the mutant reverse transcriptases obtained in Examples 1 to 4 and the initial reaction rate after heat treatment at 50 ° C. of WT obtained in Comparative Example 3 were determined. The comparison results are shown in Table 2.
  • the initial reaction rate after heat treatment at 50 ° C. for each of the mutant reverse transcriptases obtained in Examples 1 to 4 is the same as that of WT obtained in Comparative Example 3 at 50 ° C. It can be seen that the initial reaction rate after the heat treatment tends to be large. In addition, when the heat treatment at 48 ° C. was performed, the initial reaction rate after the heat treatment at 48 ° C. of each of the mutant reverse transcriptases obtained in the examples was that of the WT obtained in Comparative Example 3 at 48 ° C. There was a tendency to be larger than the initial reaction rate after the heat treatment (see, for example, Table 3).
  • the amino acid residue corresponding to at least one residue selected from the group consisting of the valine residue at position 433 and the isoleucine residue at position 434 in the sequence shown in SEQ ID NO: 2 It can be seen that substitution with a positively charged amino acid residue such as a group or a lysine residue can improve the thermal stability compared to WT.
  • Example 5 In Example 1, instead of using the V433R primer pair as the primer pair, the same operation as in Example 1 was performed except that an E286R primer pair and a V433R primer pair were used, and a mutant reverse transcriptase ( E286R / V433R).
  • E286R represents substitution of an amino acid residue corresponding to the glutamic acid residue at position 286 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • “E286R / V433R” means a multiple mutant having E286R and V433R. The obtained mutant reverse transcriptase (E286R / V433R) was confirmed to show a single band of 75 kDa as a result of SDS-PAGE.
  • the primers constituting the E286R primer pair are the primer E286R [5′-ctgaggccagaaaacgtactgtgtgggggca-3 ′ (SEQ ID NO: 15)] and the primer E286R_CP [5′-tgcccccatacgtacttttctgtggtcgtcgccccac ']
  • Example 6 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was performed, except that the D108A primer pair, the E286R primer pair, and the V433R primer pair were used.
  • Type reverse transcriptase (D108A / E286R / V433R) was obtained.
  • D108A indicates substitution of an amino acid residue corresponding to the aspartic acid residue at position 108 in the sequence shown in SEQ ID NO: 2 with an alanine residue.
  • E286R / V433R means a multiple mutant having D108A, E286R and V433R.
  • the obtained mutant reverse transcriptase (D108A / E286R / V433R) was confirmed to show a single band of 75 kDa.
  • the primers constituting the primer pair for D108A are the primer D108A [5′-aaccaggggactataatgcttataggcctgtcca-3 ′ (SEQ ID NO: 17)] and the primer D108A_CP [5′-tggacaggccttatagcccgtgtgtgtggt-3 ′ (SEQ ID NO: 17).
  • Example 7 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was performed, except that a D108R primer pair, an E286R primer pair, and a V433R primer pair were used.
  • Type reverse transcriptase (D108R / E286R / V433R) was obtained.
  • D108R represents substitution of an amino acid residue corresponding to the aspartic acid residue at position 108 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • “D108R / E286R / V433R” means a multiple mutant having D108R, E286R and V433R.
  • the obtained mutant reverse transcriptase (D108R / E286R / V433R) was confirmed to show a single band of 75 kDa.
  • the primers constituting the primer pair for D108R are primer D108R [5′-aaccaggggactataattcgttatagggcctgtcca-3 ′ (SEQ ID NO: 19)] and primer D108R_CP [5′-tggacaggccttagagttagcgtgtgtgtggt-3 ′ (SEQ ID NO: 20).
  • Example 8 In Example 1, instead of using the V433R primer pair as the primer pair, the same operation as in Example 1 was performed except that the E117A primer pair, the E286R primer pair, and the V433R primer pair were used.
  • Type reverse transcriptase (E117A / E286R / V433R) was obtained.
  • E117A indicates substitution of an amino acid residue corresponding to the glutamic acid residue at position 117 in the sequence shown in SEQ ID NO: 2 with an alanine residue.
  • “E117A / E286R / V433R” means a multiple mutant having E117A, E286R and V433R.
  • the obtained mutant reverse transcriptase (E117A / E286R / V433R) was confirmed to show a single band of 75 kDa as a result of SDS-PAGE.
  • the primers constituting the E117A primer pair are the primer E117A [5′-tccagagtctgagaggcacacaag-3 ′ (SEQ ID NO: 21)] and the primer E117A_CP [5′-ctttgtactctctcacatccgtgga-3 ′ (SEQ ID NO: 22).
  • Example 9 In Example 1, instead of using the V433R primer pair as a primer pair, the same operation as in Example 1 was performed except that an E117R primer pair, an E286R primer pair, and a V433R primer pair were used.
  • Type reverse transcriptase (E117R / E286R / V433R) was obtained.
  • E117R represents substitution of an amino acid residue corresponding to the glutamic acid residue at position 117 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • “E117R / E286R / V433R” means a multiple mutant having E117R, E286R and V433R.
  • the obtained mutant reverse transcriptase (E117R / E286R / V433R) was confirmed to show a single band of 75 kDa.
  • the primers constituting the E117R primer pair are the primer E117R [5′-tccagagtctgagagtgtcaacaag-3 ′ (SEQ ID NO: 23)] and the primer E117R_CP [5′-ctttgtacacgtctcacatcctggga-3 ′ (SEQ ID NO: 24).
  • Example 10 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was performed except that the D124A primer pair, the E286R primer pair, and the V433R primer pair were used.
  • Type reverse transcriptase (D124A / E286R / V433R) was obtained.
  • D124A represents substitution of an amino acid residue corresponding to the aspartic acid residue at position 124 in the sequence shown in SEQ ID NO: 2 with an alanine residue.
  • “D124A / E286R / V433R” means a multiple mutant having D124A, E286R and V433R.
  • the obtained mutant reverse transcriptase (D124A / E286R / V433R) was confirmed to show a single band of 75 kDa.
  • the primer constituting the D124A primer pair is the primer D124A [5′-acaagcgggtggaagcccatccaccccaccgt-3 ′ (SEQ ID NO: 25)] and the primer D124A_CP [5′-acgggtgggggtgggtgtgtccccccgtgt-3 ′ (SEQ ID NO: 26).
  • Example 11 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was performed except that a D124R primer pair, an E286R primer pair, and a V433R primer pair were used.
  • Type reverse transcriptase (D124R / E286R / V433R) was obtained.
  • D124R represents substitution of an amino acid residue corresponding to the aspartic acid residue at position 124 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • “D124R / E286R / V433R” means a multiple mutant having D124R, E286R and V433R.
  • the obtained mutant reverse transcriptase (D124R / E286R / V433R) was confirmed to show a single band of 75 kDa.
  • the primer constituting the D124R primer pair is primer D124R [5′-acagaggcgggtggaacggcatccaccccaccgt-3 ′ (SEQ ID NO: 27)] and primer D124R_CP [5′-acgggtggggtggagtgccgtccccgtgt-3 ′ (SEQ ID NO: 28).
  • Example 12 In Example 1, instead of using the V433R primer pair as the primer pair, the same operation as in Example 1 was performed except that an E286R primer pair, a V433R primer pair, and a D524A primer pair were used.
  • Type reverse transcriptase (E286R / V433R / D524A) was obtained.
  • D524A indicates substitution of an amino acid residue corresponding to the aspartic acid residue at position 524 in the sequence shown in SEQ ID NO: 2 with an alanine residue.
  • “E286R / V433R / D524A” means a multiple mutant having E286R, V433R and D524A.
  • the obtained mutant reverse transcriptase (E286R / V433R / D524A) was confirmed to show a single band of 75 kDa as a result of SDS-PAGE.
  • the primers constituting the primer pair for D524A are the primer D524A [5′-caaccctgggtacacagctggaagcagtctc-3 ′ (SEQ ID NO: 29)] and the primer D524A_CP [5′-gagagtgccctcgtgtgtgtgtgtggtgtggtgtggtgtgtggtgtgtggtgtgtggtgtgtggtgtgtggtgtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtgtggtg
  • Example 13 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was used except that a D108A primer pair, an E286R primer pair, a V433R primer pair, and a D524A primer pair were used. The operation was performed to obtain a mutant reverse transcriptase (D108A / E286R / V433R / D524A). “D108A / E286R / V433R / D524A” means a multiple mutant having D108A, E286R, V433R and D524A. The obtained mutant reverse transcriptase (D108A / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa as a result of SDS-PAGE.
  • Example 14 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was used except that the D108R primer pair, the E286R primer pair, the V433R primer pair, and the D524A primer pair were used. The operation was performed to obtain a mutant reverse transcriptase (D108R / E286R / V433R / D524A). “D108R / E286R / V433R / D524A” means a multiple mutant having D108R, E286R, V433R and D524A. As a result of SDS-PAGE, the obtained mutant reverse transcriptase (D108R / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa.
  • Example 15 In Example 1, instead of using the V433R primer pair as the primer pair, the same as Example 1 except that the E117A primer pair, the E286R primer pair, the V433R primer pair, and the D524A primer pair were used. The operation was performed to obtain a mutant reverse transcriptase (E117A / E286R / V433R / D524A). “E117A / E286R / V433R / D524A” means multiple mutants having E117A, E286R, V433R and D524A.
  • the obtained mutant reverse transcriptase (E117A / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa.
  • the obtained mutant reverse transcriptase (E117A / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa.
  • Example 16 In Example 1, instead of using the V433R primer pair as the primer pair, the same as Example 1 except that the E117 primer pair, the E286R primer pair, the V433R primer pair, and the D524A primer pair were used. The operation was performed to obtain a mutant reverse transcriptase (E117R / E286R / V433R / D524A). “E117R / E286R / V433R / D524A” means multiple mutants having E117R, E286R, V433R and D524A. As a result of SDS-PAGE, the obtained mutant reverse transcriptase (E117R / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa.
  • Example 17 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was used except that the D124A primer pair, the E286R primer pair, the V433R primer pair, and the D524A primer pair were used. The operation was performed to obtain a mutant reverse transcriptase (D124A / E286R / V433R / D524A). “D124A / E286R / V433R / D524A” means a multiple mutant having D124A, E286R, V433R and D524A. The obtained mutant reverse transcriptase (D124A / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa as a result of SDS-PAGE.
  • Example 18 In Example 1, instead of using the V433R primer pair as the primer pair, the same procedure as in Example 1 was used except that the D124R primer pair, the E286R primer pair, the V433R primer pair, and the D524A primer pair were used. The operation was performed to obtain a mutant reverse transcriptase (D124R / E286R / V433R / D524A). “D124R / E286R / V433R / D524A” means a multiple mutant having D124R, E286R, V433R and D524A. The obtained mutant reverse transcriptase (D124R / E286R / V433R / D524A) was confirmed to show a single band of 75 kDa as a result of SDS-PAGE.
  • Test example 3 200 ⁇ L of the incubation solution 200 ⁇ L of the mutant reverse transcriptase obtained in Examples 1, 2, 5 to 18 or the WT obtained in Comparative Example 3 so that the concentration of the mutant reverse transcriptase or WT is 30 nM. Added to. The obtained mixture was incubated at 46 ° C., 48 ° C., 50 ° C. or 52 ° C. for 10 minutes to obtain the mutant reverse transcriptase obtained in Examples 1, 2, 5 to 18 or Comparative Example 3. The WT was heat treated. Next, a mixture containing mutant reverse transcriptase after heat treatment or WT after heat treatment was incubated on ice for 30 to 60 minutes.
  • the mutant reverse transcriptase after the heat treatment or the WT after the heat treatment is added to the reaction solution so that the concentration of the mutant reverse transcriptase after the heat treatment or the WT after the heat treatment is 30 nM.
  • the resulting mixture was incubated at 37 ° C. to perform a reverse transcriptase reaction.
  • the glass filter was dried.
  • the glass filter was placed in 2.5 mL of a liquid scintillation reagent (National Diagnostics, product name: Ecoscint H), and the radioactivity was counted with a liquid scintillation counter. The dTTP uptake amount was calculated based on the radioactivity.
  • the initial reaction rate was calculated based on the change in dTTP uptake over time.
  • the residual activity was calculated based on the formula represented by the formula (I).
  • Table 4 shows the results of examining the relationship between the test sample and the initial reaction rate after heat treatment at 46 ° C, 48 ° C, 50 ° C or 52 ° C in Test Example 3. Moreover, the result of investigating the relationship between the test sample and the residual activity after heat treatment in Test Example 3 is shown in FIG. In the figure, lane 1 is the mutant reverse transcriptase (V433R) obtained in Example 1, lane 2 is the mutant reverse transcriptase (V433K) obtained in Example 2, and lane 3 is obtained in Example 5.
  • Mutant reverse transcriptase (E286R / V433R), lane 4 is the mutant reverse transcriptase obtained in Example 6 (D108A / E286R / V433R), and lane 5 is the mutant reverse transcriptase obtained in Example 7. (D108R / E286R / V433R), lane 6 is the mutant reverse transcriptase obtained in Example 8 (E117A / E286R / V433R), and lane 7 is the mutant reverse transcriptase obtained in Example 9 (E117R / E286R).
  • lane 8 is the mutant reverse transcriptase obtained in Example 10 (D124A / E286R / V433R), and lane 9 is the mutant reverse transcriptase obtained in Example 11.
  • D124R / E286R / V433R Lane 10 is the mutant reverse transcriptase obtained in Example 12 (E286R / V433R / D524A)
  • Lane 11 is the mutant reverse transcriptase obtained in Example 13 (D108A / E286R / V433R / D524A)
  • Lane 12 is the mutant reverse transcriptase obtained in Example 14 (D108R / E286R / V433R / D524A)
  • Lane 13 is the mutant reverse transcriptase obtained in Example 15 (E117A / E286R /).
  • lane 14 is the mutant reverse transcriptase obtained in Example 16 (E117R / E286R / V433R / D524A), and lane 15 is the mutant reverse transcriptase obtained in Example 17 (D124A / E286R / V433R / D524A), lane 16 is the mutant type obtained in Example 18. Transcriptase (D124R / E286R / V433R / D524A) and lane 17 shows a WT obtained in Comparative Example 3.
  • the shaded bar indicates the remaining activity after heat treatment at 46 ° C.
  • the lattice bar indicates the remaining activity after heat treatment at 48 ° C.
  • the black bar indicates the remaining activity after heat treatment at 50 ° C.
  • the white bar indicates 52 ° C. The residual activity after heat treatment is shown.
  • WT obtained in Comparative Example 3 was completely inactivated by heat treatment at 52 ° C.
  • mutant reverse transcriptase obtained in Examples 1, 2, and 5 to 18 It can be seen that sufficient reverse transcriptase activity is obtained even by heat treatment at ° C.
  • amino acid residue corresponding to the valine residue at position 433 in the sequence shown in SEQ ID NO: 2 is substituted with a positively charged amino acid residue such as an arginine residue or a lysine residue
  • SEQ ID NO: 2 At least selected from the group consisting of aspartic acid residue at position 108, glutamic acid residue at position 117, aspartic acid residue at position 124, glutamic acid residue at position 286 and aspartic acid residue at position 524 in the sequence shown.
  • an amino acid residue corresponding to at least one residue selected from the group consisting of a valine residue at position 433 and an isoleucine residue at position 434 in the sequence shown in SEQ ID NO: 2 is a positively charged amino acid.
  • Aspartic acid residue at position 108, glutamic acid residue at position 117, aspartic acid residue at position 124, glutamic acid residue at position 286, and position 524 at position 524 in the sequence shown in SEQ ID NO: 2 By substituting an amino acid residue corresponding to at least one residue selected from the group consisting of aspartic acid residues with a positively charged amino acid residue or a nonpolar amino acid residue, the thermal stability is significantly higher than that of WT. It can be seen that the mutated reverse transcriptase is obtained.
  • Test example 4 In Examples 1 to 18, when the mutant reverse transcriptase of the present invention (Examples 1 to 18) is expressed in a host cell, fractionation is easier than when WT is expressed in a host cell. There was a trend. Therefore, the expression pattern of the target protein and the contaminating protein produced when the mutant reverse transcriptase of the present invention (Examples 1 to 18) was expressed in the host cell was examined.
  • Example 19 V433R mutant expression plasmid (Example 19), V433K mutant expression plasmid (Example 20), WT expression plasmid obtained in Production Example 1 (Comparative Example 4) or E302K mutant expression plasmid (Comparative Example 5) ) was used to transform E. coli BL21 (DE3), which is a host cell. The obtained cells were used at 30 ° C.
  • a soluble fraction containing an enzyme (V433K) (Example 20), a soluble fraction containing WT (Comparative Example 4) or a soluble fraction containing a mutant reverse transcriptase (E302K) (Comparative Example 5) was obtained. It was.
  • lane 1 is a soluble fraction containing WT (Comparative Example 4)
  • lane 2 is a soluble fraction containing a mutant reverse transcriptase (V433R) (Example 19)
  • lane 3 is a mutant reverse transcriptase.
  • a soluble fraction containing (V433K) (Example 20)
  • lane 4 shows a soluble fraction containing mutant reverse transcriptase (E302K) (Comparative Example 5).
  • the intensity of the 75 kDa band corresponding to the enzyme was shown to be higher than the intensity of the 75 kDa band in the soluble fraction containing WT and the soluble fraction containing the mutant reverse transcriptase (E302K).
  • the intensity of the contaminating protein band in the soluble fraction containing the mutant reverse transcriptase (V433R) and the soluble fraction containing the mutant reverse transcriptase (V433K) It was shown to be comparable to the intensity of the contaminating protein band in the soluble fraction containing mutant reverse transcriptase (E302K).
  • the difference in intensity of the 75 kDa band is the same regardless of the type of vector used for the production of the expression plasmid. The same tendency is also observed for each of the mutant reverse transcriptases obtained in Examples 3 to 18.
  • mutant reverse transcriptase of the present invention can be easily separated from other contaminating proteins and is excellent in industrial productivity.
  • Example 1 instead of using the V433R primer pair as the primer pair, the F303R primer pair (Example 21), the F303K primer pair (Example 22), the L432R primer pair (Example 23) or the L432K primer Except for using the pair (Example 24), the same operation as in Example 1 was performed, and mutant reverse transcriptase (F303R) (Example 21), mutant reverse transcriptase (F303K) (Example 22). Mutant reverse transcriptase (L432R) (Example 23) or mutant reverse transcriptase (L432K) (Example 24) was obtained.
  • F303R represents substitution of an amino acid residue corresponding to the phenylalanine residue at position 303 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • F303K represents substitution of an amino acid residue corresponding to the phenylalanine residue at position 303 in the sequence shown in SEQ ID NO: 2 with a lysine residue.
  • L432R indicates substitution of an amino acid residue corresponding to the leucine residue at position 432 in the sequence shown in SEQ ID NO: 2 with an arginine residue.
  • L432K indicates substitution of an amino acid residue corresponding to the leucine residue at position 432 in the sequence shown in SEQ ID NO: 2 with a lysine residue.
  • Primers constituting the primer pair for F303R are the primer F303R (5′-gacaactaaggggagcgcctagggacggcag-3 ′) (SEQ ID NO: 31) and the primer F303R_CP (5′-ctgccgtccctagcccctgtgtgtgtc32 ′) (sequence No. 31).
  • Primers constituting the primer pair for F303K are the primer F303K (5′-gacaactagggagaaactaggggacggcag-3 ′) (SEQ ID NO: 33) and the primer F303K_CP (5′-ctgccgtcccttttcccttgtcgtgtcgtgtc34 ′ (sequence No. 33).
  • the primers constituting the L432R primer pair are the primer L432R (5′-ccatgggacaccccacgtgtcattctggccc-3 ′) (SEQ ID NO: 35) and the primer L432R_CP (5′-ggcccagaatgaccgtggtgtcccatgg-3 ′) (SEQ ID NO: 36).
  • the primers constituting the L432K primer pair are the primer L432K (5′-ccatgggacacccaaaaagtattctggcc-3 ′) (SEQ ID NO: 37) and the primer L432K_CP (5′-ggccccagaatgactttgtcgtgtccctgg-3 ′) (sequence number: 38).
  • Example 24 Mutant reverse transcriptase (F303R) (Example 21), mutant reverse transcriptase (F303K) (Example 22), mutant reverse transcriptase (L432R) (Example 23) and mutant reverse transcriptase (L432K) As a result of SDS-PAGE, Example 24 was confirmed to show a single band of 75 kDa.
  • mutant reverse transcriptase (F303R) (Example 21), mutant reverse transcriptase (F303K) (Example 22), mutant reverse transcriptase (L432R) (Example 23) and mutant reverse transcriptase ( L432K) (Example 24) was measured for the initial reaction rate and residual activity after the heat treatment at 50 ° C. by performing the same operations as in Test Example 2 (2).
  • amino acid residue corresponding to at least one residue selected from the group consisting of aspartic acid residue at position 117, glutamic acid residue at position 117, aspartic acid residue at position 124, glutamic acid residue at position 286 and aspartic acid residue at position 524 Substituting a positively charged amino acid residue such as an arginine residue or a nonpolar amino acid residue such as an alanine residue. That the thermal stability of the mutant reverse transcriptase, is greatly improved as compared with the thermal stability of the WT
  • Test Example 5 From the results obtained in Test Example 2, a mutant reverse transcriptase having a substitution of a residue corresponding to the valine residue at position 433 of SEQ ID NO: 2 with an arginine residue or a lysine residue (Examples 1 and 2). ) Has higher thermal stability than WT.
  • the mutant reverse transcriptase of the present invention is more industrially productive than the mutant reverse transcriptase having a substitution of a residue corresponding to the glutamic acid residue at position 302 of SEQ ID NO: 2 with a lysine residue. It is suggested to be excellent.
  • the thermal stability of the mutant reverse transcriptase obtained in Examples 1, 5, 7 and 14 was changed to a multiple mutation in which the glutamic acid residue at position 302 was substituted with a lysine residue. Comparison was made with the thermal stability of each of the type reverse transcriptases “E286R / E302K / L435R” and “E286R / E302K / L435R / D524A”.
  • Example 1 a mutant reverse transcriptase (D524A) was obtained by performing the same operation as in Example 1 except that the D524A primer pair was used instead of the V433R primer as the primer pair.
  • Example 1 the same procedure as in Example 1 was used, except that the E286R primer pair, the E302K primer pair, and the L435R primer pair were used instead of the V433R primer as the primer pair.
  • a photoenzyme (E286R / E302K / L435R) was obtained.
  • Example 1 the same operation as in Example 1 was performed except that the E286R primer pair, the E302K primer pair, the L435R primer pair and the D524A primer pair were used instead of the V433R primer as the primer pair.
  • a mutant reverse transcriptase (E286R / E302K / L435R / D524A) was obtained.
  • the mutant reverse transcriptase (D524A), the mutant reverse transcriptase (E286R / E302K / L435R) and the mutant reverse transcriptase (E286R / E302K / L435R / D524A) are 75 kDa single by SDS-PAGE. It was confirmed that this band was shown.
  • the resulting mixture was incubated at 50 ° C. for 10 minutes to heat-treat the mutant reverse transcriptase or WT.
  • a mixture containing mutant reverse transcriptase after heat treatment or WT after heat treatment was incubated on ice for 30 to 60 minutes.
  • the mutant reverse transcriptase after the heat treatment or the WT after the heat treatment is added to the reaction solution so that the concentration of the mutant reverse transcriptase after the heat treatment or the WT after the heat treatment is 5 nM.
  • the obtained mixture was incubated at 37 ° C., and then a reverse transcription reaction was performed. Thereafter, the same operation as in Test Example 3 was performed to calculate the initial reaction rate of dTTP uptake, and the residual activity (%) when the initial reaction rate before heat treatment was 100% was calculated.
  • the results of examining the relationship between the test sample and the residual activity after heat treatment in Test Example 4 are shown in Table 5 and FIG.
  • the test sample numbers in FIG. 6 correspond to the test sample numbers in Table 5.
  • the mutant reverse transcriptase obtained in Example 7 or 14 has the same thermal stability as E286R / E302K / L435R and E286R / E302K / L435R / D524A. I understand that. From these results, among the residues corresponding to the hydrophobic amino acid residues (see FIG. 7) present on the hydrophobic surface including the hydrophobic amino acid residues that are contiguous in the three-dimensional structure in the connection domain of wild-type reverse transcriptase.
  • the mutant reverse transcriptase of the present invention has a hydrophobic amino acid residue (see FIG. 7) present on the hydrophobic surface including a hydrophobic amino acid residue that is continuous in three-dimensional structure in the connection domain of the wild type reverse transcriptase. Since at least one of the corresponding residues is substituted with a positively charged amino acid residue, it has high thermal stability and is efficient even under temperature conditions in which formation of RNA secondary structure is suppressed It is suggested that the reverse transcription reaction can be performed well, has high versatility, and is excellent in industrial productivity. In addition, in the present invention, it is suggested that it is desirable that the mutation of the glutamic acid residue at position 302 is not included from the viewpoint of ensuring both high industrial productivity and high thermal stability in a balanced manner.
  • the mutant reverse transcriptase of the present invention since the mutant reverse transcriptase of the present invention has high thermal stability, it exhibits high reverse transcriptase activity even when used for reactions at high reaction temperatures. To do. Therefore, according to the mutant reverse transcriptase of the present invention, even when the RNA used as the template contains a sequence that easily forms a secondary structure, the reaction temperature during the reverse transcription reaction is set to a high temperature. Thereby, formation of the secondary structure of RNA can be suppressed and a reverse transcription reaction can be performed. Therefore, the mutant reverse transcriptase of the present invention is not limited to the RNA-containing sample to be used and is a highly versatile analytical reagent (for example, reverse transcription reaction kit), a reagent for detecting viruses, bacteria, diseases, etc. It is suggested to be useful as (for example, a detection kit). In addition, the mutant reverse transcriptase of the present invention is excellent in industrial productivity.
  • a highly versatile analytical reagent for example, reverse transcription reaction kit
  • Example 1 Examples of reverse transcription reaction kits are shown below.
  • Reverse transcription reaction kit -Mutant reverse transcriptase obtained in Example 1-10x reverse transcriptase buffer [Composition: 250 mM Tris-HCl buffer (pH 8.3), 500 mM potassium chloride, 20 mM dithiothreitol] -2.0 mM dNTP mixture-10 ⁇ M (for standard RNA amplification) primer aqueous solution-Standard RNA solution (1.6 pg / ⁇ L)
  • Example 25 Examples of detection kits are shown below.
  • (Detection kit) -Mutant reverse transcriptase obtained in Example 1-10x reverse transcriptase buffer [Composition: 250 mM Tris-HCl buffer (pH 8.3), 500 mM potassium chloride, 20 mM dithiothreitol] -2.0 mM dNTP mixture-10 ⁇ M RV-R26 primer aqueous solution-Standard RNA solution (1.6 pg / ⁇ L) -E. coli RNA solution (1.0 ⁇ g / ⁇ L)
  • SEQ ID NO: 3 is the sequence of primer V433R.
  • SEQ ID NO: 4 is the sequence of primer V433R_CP.
  • SEQ ID NO: 5 is the sequence of primer V433K.
  • SEQ ID NO: 6 is the sequence of primer V433K_CP.
  • SEQ ID NO: 7 is the sequence of primer I434R.
  • SEQ ID NO: 8 is the sequence of primer I434R_CP.
  • SEQ ID NO: 9 is the sequence of primer I434K.
  • SEQ ID NO: 10 is the sequence of primer I434K_CP.
  • SEQ ID NO: 11 is the sequence of primer L304R.
  • SEQ ID NO: 12 is the sequence of primer L304R_CP.
  • SEQ ID NO: 13 is the sequence of primer L304K.
  • SEQ ID NO: 14 is the sequence of primer L304K_CP.
  • SEQ ID NO: 15 is the sequence of primer E286R.
  • SEQ ID NO: 16 is the sequence of primer E286R_CP.
  • SEQ ID NO: 17 is the sequence of primer D108A.
  • SEQ ID NO: 18 is the sequence of primer D108A_CP.
  • SEQ ID NO: 19 is the sequence of primer D108R.
  • SEQ ID NO: 20 is the sequence of primer D108R_CP.
  • SEQ ID NO: 21 is the sequence of primer E117A.
  • SEQ ID NO: 22 is the sequence of primer E117A_CP.
  • SEQ ID NO: 23 is the sequence of primer E117R.
  • SEQ ID NO: 24 is the sequence of primer E117R_CP.
  • SEQ ID NO: 25 is the sequence of primer D124A.
  • SEQ ID NO: 26 is the sequence of primer D124A_CP.
  • SEQ ID NO: 27 is the sequence of primer D124R.
  • SEQ ID NO: 28 is the sequence of primer D124R_CP.
  • SEQ ID NO: 29 is the sequence of primer D524A.
  • SEQ ID NO: 30 is the sequence of primer D524A_CP.
  • SEQ ID NO: 31 is the sequence of primer F303R.
  • SEQ ID NO: 32 is the sequence of primer F303R_CP.
  • SEQ ID NO: 33 is the sequence of primer F303K.
  • SEQ ID NO: 34 is the sequence of primer F303K_CP.
  • SEQ ID NO: 35 is the sequence of primer L432R.
  • SEQ ID NO: 36 is the sequence of primer L432R_CP.
  • SEQ ID NO: 37 is the sequence of primer L432K.
  • SEQ ID NO: 38 is the sequence of primer L432K_

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne: une transcriptase inverse variante qui contient un domaine correspondant à un domaine de liaison d'une transcriptase inverse de type sauvage et dans laquelle, sur une surface hydrophobe contenant des restes d'acides aminés hydrophobes ayant une conformation consécutive dans ledit domaine, au moins un des restes d'acides aminés hydrophobes est remplacé par un résidu d'acides aminés à charge positive; un moyen de fournir ladite transcriptase inverse variante; et l'utilisation de celle-ci.
PCT/JP2013/081677 2013-11-25 2013-11-25 Transcriptase inverse variante Ceased WO2015075842A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2013/081677 WO2015075842A1 (fr) 2013-11-25 2013-11-25 Transcriptase inverse variante

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2013/081677 WO2015075842A1 (fr) 2013-11-25 2013-11-25 Transcriptase inverse variante

Publications (1)

Publication Number Publication Date
WO2015075842A1 true WO2015075842A1 (fr) 2015-05-28

Family

ID=53179144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/081677 Ceased WO2015075842A1 (fr) 2013-11-25 2013-11-25 Transcriptase inverse variante

Country Status (1)

Country Link
WO (1) WO2015075842A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189184A1 (fr) * 2017-04-11 2018-10-18 Roche Diagnostics Gmbh Transcriptase inverse mutante présentant une stabilité thermique accrue ainsi que produits, procédés et utilisations impliquant ladite transcriptase inverse mutante
JP2023541511A (ja) * 2020-07-20 2023-10-03 インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド 活性および熱安定性が向上した逆転写酵素変異体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516072A (ja) * 2008-04-10 2011-05-26 フェルメンタス ユーエービー 核酸の生成
WO2012020759A1 (fr) * 2010-08-13 2012-02-16 国立大学法人京都大学 Transcriptase inverse variante

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516072A (ja) * 2008-04-10 2011-05-26 フェルメンタス ユーエービー 核酸の生成
WO2012020759A1 (fr) * 2010-08-13 2012-02-16 国立大学法人京都大学 Transcriptase inverse variante

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AREZI, B. ET AL.: "Novel mutations in Moloney murine leukemia virus reverse transcriptase increase thermostability through tighter binding to template-primer", NUCLEIC ACIDS RESEARCH, vol. 37, no. 2, 2009, pages 473 - 481 *
DAS, D. ET AL.: "A directed approach to improving the solubility of Moloney murine leukemia virus reverse transcriptase", PROTEIN SCIENCE, vol. 10, 2001, pages 1936 - 1941 *
DAS, D. ET AL.: "The crystal structure of the monomeric reverse transcriptase from Moloney murine leukemia virus", STRUCTURE, vol. 12, 2004, pages 819 - 829 *
JENKINS, T.M. ET AL.: "Catalytic domain of human immunodeficiency virus type 1 integrase: Identification of a soluble mutant by systematic replacement of hydrophobic residues", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 6057 - 6061 *
MIZUNO, M. ET AL.: "Insight into the mechanism of the stabilization of Moloney murine leukemia virus reverse transcriptase by eliminating RNase H activity", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 74, no. 2, 2010, pages 440 - 442 *
YASUKAWA, K. ET AL.: "Increase in thermal stability of Moloney murine leukemia virus reverse transcriptase by site-directed mutagenesis", J. BIOTECHNOL., vol. 150, 2010, pages 299 - 306 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189184A1 (fr) * 2017-04-11 2018-10-18 Roche Diagnostics Gmbh Transcriptase inverse mutante présentant une stabilité thermique accrue ainsi que produits, procédés et utilisations impliquant ladite transcriptase inverse mutante
JP2020516272A (ja) * 2017-04-11 2020-06-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増大した熱安定性を有する変異型逆転写酵素、ならびにそれに関する生成物、方法および使用
US11618892B2 (en) 2017-04-11 2023-04-04 Roche Diagnostics Operations, Inc. Mutant reverse transcriptase with increased thermal stability as well as products, methods and uses involving the same
US12234488B2 (en) 2017-04-11 2025-02-25 Roche Diagnostics Operations, Inc. Mutant reverse transcriptase with increased thermal stability as well as products, methods and uses involving the same
JP2023541511A (ja) * 2020-07-20 2023-10-03 インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド 活性および熱安定性が向上した逆転写酵素変異体
EP4182449A4 (fr) * 2020-07-20 2024-10-09 Integrated DNA Technologies Inc. Mutants de transcriptase inverse présentant une activité et une thermostabilité accrues
US12435318B2 (en) 2020-07-20 2025-10-07 Integrated Dna Technologies, Inc. Reverse transcriptase mutants with increased activity and thermostability

Similar Documents

Publication Publication Date Title
JP6180002B2 (ja) 変異型逆転写酵素
US11111508B2 (en) Modified CAS9 compositions and methods of use
JP2014082936A (ja) 変異型逆転写酵素
CN102421892A (zh) 二鸟苷酸环化酶、其生产方法及其在制备环化-di-GMP及其类似物中的应用
CN112175980A (zh) 通过定点突变提高聚合酶大片段活性的方法及应用
CN113302299A (zh) 阿洛酮糖差向异构酶变体、其生产方法以及使用其生产阿洛酮糖的方法
US20130189757A1 (en) Affinity purification of rna under native conditions based on the lambda boxb/n peptide interaction
WO2018107521A1 (fr) T4 polynucléotide kinase recombinase et procédé de préparation, gène d'expression, vecteur d'expression et cellule hôte associés
US20170260518A1 (en) Methionine lyase, encoding gene and biosynthetic method thereof
Abeldenov et al. Cloning, expression and purification of recombinant analog of Taq DNA polymerase
JP7363063B2 (ja) 変異型ｄｎａポリメラーゼ
JP2022539560A (ja) 配列決定反応のための重合酵素
WO2015075842A1 (fr) Transcriptase inverse variante
KR20240053585A (ko) 카고 뉴클레오티드 서열을 전이시키기 위한 시스템 및 방법
CN117187210B (zh) 一种突变型Bst DNA聚合酶大片段及其制备方法
JP2013165669A (ja) 変異型逆転写酵素
CN106148307B (zh) 一种碱性蛋白酶及其编码基因和它们的应用
CN113832127A (zh) 一种限制性内切酶BamHⅠ的突变体及其应用
CN114381442B (zh) 一种可快速延伸的高保真dna聚合酶及其制备方法和应用
CN112662642A (zh) 突变型鱼大眼梭鲈皮肤肉瘤病毒逆转录酶及其应用
CN112143721B (zh) 低温过氧化氢酶及其制备方法和应用
JP5357445B2 (ja) 環状核酸の単離方法
JP2025102588A (ja) 改変型ｒｎａポリメラーゼ
WO2023098036A1 (fr) Mutant d'enzyme taq, son procédé de préparation et son application
CN107236718B (zh) 一种来源于宏基因组的低温酯酶、编码基因及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13897938

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13897938

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP